HighVista Strategies LLC holds a diversified book of 156 stocks worth $362.2M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Oruka Therapeutics Inc and trimmed Cogent Biosciences Inc. Their largest long position is Invesco DB Commodity Index T at 8% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1335325/holdings"
Use Arkolith to show HighVista Strategies LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
96% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Invesco DB Commdy Indx TRCK UNIT | $30.6M | 1.06M | 8.5% | —Held | |
| 2 | Abivax Sa SPONSORED ADS | $12.6M | 113.3K | 3.5% | ▲+57% Added · +41K sh | |
| 3 | Praxis Precision Medicines I COM NEW | $8.5M | 26.3K | 2.3% | ▲+1.9% Added · +482 sh | |
| 4 | Cogent Biosciences Inc COM | $7.6M | 197.1K | 2.1% | ▼−41% Reduced · −140K sh | |
| 5 | Spyre Therapeutics Inc COM NEW | $7.4M | 146.3K | 2.0% | ▼−22% Reduced · −42K sh | |
| 6 | Vaxcyte Inc COM | $7.2M | 124.6K | 2.0% | ▲+9.3% Added · +11K sh | |
| 7 | Revolution Medicines Inc COM | $6.7M | 69.3K | 1.9% | ▼−42% Reduced · −51K sh | |
| 8 | Terns Pharmaceuticals Inc COM | $6.0M | 114.3K | 1.7% | ▼−35% Reduced · −61K sh | |
| 9 | Structure Therapeutics Inc SPONSORED ADS | $6.0M | 123.9K | 1.6% | ▼−36% Reduced · −69K sh | |
| 10 | Nuvalent Inc COM | $5.8M | 56.6K | 1.6% | ▼−23% Reduced · −17K sh | |
| 11 | Immunovant Inc COM | $5.6M | 225.1K | 1.5% | ▲+1.5% Added · +3K sh | |
| 12 | Soleno Therapeutics Inc COM | $5.5M | 165.2K | 1.5% | ▲+22% Added · +30K sh | |
| 13 | Tyra Biosciences Inc COM | $5.0M | 131.3K | 1.4% | ▲+274% Added · +96K sh | |
| 14 | Amylyx Pharmaceuticals Inc COM | $4.9M | 352.1K | 1.4% | ▲+47% Added · +113K sh | |
| 15 | Amazon Com Inc COM | $4.7M | 22.4K | 1.3% | ▲+29% Added · +5K sh | |
| 16 | LB Pharmaceuticals Inc COM SHS | $4.3M | 173.6K | 1.2% | ▲+24% Added · +33K sh | |
| 17 | Relay Therapeutics Inc COM | $4.2M | 421.9K | 1.2% | ▼−23% Reduced · −123K sh | |
| 18 | Insmed Inc COM PAR $.01 | $4.0M | 24.3K | 1.1% | ▼−38% Reduced · −15K sh | |
| 19 | Nvidia Corporation COM | $3.9M | 22.4K | 1.1% | ▲+58% Added · +8K sh | |
| 20 | Oruka Therapeutics Inc COM | $3.9M | 78.9K | 1.1% | ▲New New position | |
| 21 | Cytokinetics Inc COM NEW | $3.9M | 58.6K | 1.1% | ▼−49% Reduced · −56K sh | |
| 22 | Liquidia Corporation COM NEW | $3.8M | 99.7K | 1.0% | ▼−36% Reduced · −56K sh | |
| 23 | Ocular Therapeutix Inc COM | $3.7M | 441.6K | 1.0% | ▲+28% Added · +98K sh | |
| 24 | Tarsus Pharmaceuticals Inc COM | $3.7M | 52.5K | 1.0% | ▼−2.0% Reduced · −1K sh | |
| 25 | Bridgebio Pharma Inc COM | $3.7M | 49.6K | 1.0% | ▼−38% Reduced · −31K sh | |
| 26 | Moonlake Immunotherapeutics CLASS A ORD | $3.6M | 194.0K | 1.0% | ▲New New position | |
| 27 | Argenx SE SPONSORED ADR | $3.6M | 4.9K | 1.0% | ▲+37% Added · +1K sh | |
| 28 | Protagonist Therapeutics Inc COM | $3.6M | 33.9K | 1.0% | ▼−54% Reduced · −40K sh | |
| 29 | Palisade Bio Inc COM | $3.5M | 2.02M | 1.0% | ▲+55% Added · +719K sh | |
| 30 | Definium Therapeutics Inc COM SHS | $3.5M | 185.9K | 1.0% | ▲New New position | |
| 31 | Nurix Therapeutics Inc COM | $3.5M | 226.5K | 1.0% | ▲New New position | |
| 32 | Axsome Therapeutics Inc. COM | $3.5M | 20.4K | 1.0% | ▲+84% Added · +9K sh | |
| 33 | Inventiva Sa ADS | $3.4M | 615.7K | 0.9% | ▲New New position | |
| 34 | Dyne Therapeutics Inc COM | $3.3M | 182.9K | 0.9% | ▲+207% Added · +123K sh | |
| 35 | Apogee Therapeutics Inc COM | $3.0M | 35.8K | 0.8% | ▼−60% Reduced · −53K sh | |
| 36 | GH Research PLC ORDINARY SHARES | $3.0M | 213.2K | 0.8% | ▼−11% Reduced · −27K sh | |
| 37 | Dianthus Therapeutics Inc COM | $3.0M | 35.6K | 0.8% | ▼−27% Reduced · −13K sh | |
| 38 | Maze Therapeutics Inc COM | $3.0M | 99.8K | 0.8% | ▼−41% Reduced · −71K sh | |
| 39 | Erasca Inc COM | $2.9M | 181.1K | 0.8% | ▲New New position | |
| 40 | Edgewise Therapeutics Inc COM | $2.9M | 91.9K | 0.8% | ▼−46% Reduced · −79K sh | |
| 41 | Enliven Therapeutics Inc COM | $2.9M | 73.1K | 0.8% | ▼−11% Reduced · −9K sh | |
| 42 | Xenon Pharmaceuticals Inc COM | $2.9M | 49.0K | 0.8% | ▲New New position | |
| 43 | Celldex Therapeutics Inc New COM NEW | $2.8M | 89.4K | 0.8% | ▲+73% Added · +38K sh | |
| 44 | Vera Therapeutics Inc CL A | $2.8M | 69.2K | 0.8% | ▲New New position | |
| 45 | Pharvaris N V COM | $2.8M | 97.9K | 0.8% | ▼−40% Reduced · −65K sh | |
| 46 | Viridian Therapeutics Inc COM | $2.6M | 134.2K | 0.7% | ▼−64% Reduced · −238K sh | |
| 47 | Alkermes PLC SHS | $2.6M | 73.2K | 0.7% | ▲+177% Added · +47K sh | |
| 48 | Alumis Inc COM | $2.5M | 112.9K | 0.7% | ▲New New position | |
| 49 | Microsoft Corp COM | $2.4M | 6.5K | 0.7% | ▼−1.2% Reduced · −80 sh | |
| 50 | Eyepoint Inc COM NEW | $2.4M | 183.0K | 0.7% | ▲New New position |
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.